Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06877143

Hypercaloric PEG Nutrition in ALS to Sustain Energy Homeostasis

Weight loss is a known negative prognostic factor in amyotrophic lateral sclerosis (ALS). Over the last years, various interventional studies targeting the energy deficit in ALS yielded promising results; however,it is still unclear which kind of nutrition or nutritional supplement is most beneficial. Moreover, there is lack of evidence regarding interventions in patients with a PEG in later disease stages.In a pilot study conducted in 2013, it was demonstrated that body weight can be stabilized in ALS by applying either a fat-rich or carbohydrate-rich high-caloric food supplement. In 2014, Wills et al. conducted a placebo-controlled randomized controlled pilot study, which indicated that a carbohydrate-rich, hypercaloric diet, consisting in 125% of estimated energy requirements as determined by indirect calorimetry, in patients fed via percutaneous endoscopic gastrostomy was safe and well tolerated. Moreover, these patients showed longer survival than patients fed with a fat-rich, hypercaloric diet or an isocaloric diet . Hypercaloric, high-carbohydrate diet also showed beneficial effects on body weight and Body Mass Index . Although these results were promising, the low number of patients (n=24) was a severe limiting factor of this study. The aim of this study is to investigate the effect of a hypercaloric PEG nutrition, consisting of 120% of estimated calorie requierements, compared to an isocaloric nutrition. Individual energy requirement is determined by performing indirect calorimetry and activity questionnaire. The investigators hypothsize, that a hypercaloric PEG nutrition slows down disease progression as measured by neurofilament light chains (NfL) in serum after 6 months compared to placebo. Power calculation relies on the results of the lipids and calories for ALS (LIPCAL-ALS) study which tested the effect of an oral high-caloric fatty nutritional supplement in ALS. The study revealed that NfL serum values declined significantly in the intervention group while remaining stable in the placebo group over the course of the study. Assuming a similar effect size, we calculated that 76 patients had to be included in the current trial.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Ulm Universita, Department of Neurology

Ulm, Baden-Wurttemberg, 89081, Germany

Location status: Recruiting

Location contact

Christine Herrmann, Dr.

CONTACT

[email protected]

0049 731 177 5374

Christine Herrmann, Dr.

PRINCIPAL_INVESTIGATOR

Johannes Dorst, Prof. Dr.

SUB_INVESTIGATOR

About this study

Patients eligible for study participation will be randomized to one of two groups (hypercaloric or isocaloric diet) at baseline visit. Intervention or control diet will be administered as an add-on to standard therapy. Calory requirement will be individually determined by indirect calorimetry which measures resting energy expenditure (REE) and by collecting physical activity data. Indirect calorimetry is a non-invasive procedure which allows to calculate resting energy expenditure by measuring carbon dioxide and oxygen in the expired air using a canopy hood or a full-face mask. For both groups, a standard PEG nutrition featuring a balanced ratio of fat, carbohydrates, and protein according to human requirements will be used (e.g. Fresenius Fresubin® Energy Fibre/2250 Complete).

PEG nutrition used in this study (e.g. Fresenius Fresubin® Energy Fibre/2250 Complete) is routinely used in clinical practice for feeding of patients with ALS and PEG. It is known to be well tolerable and safe. In few cases of intolerance, this standard tube feeding may be switched to another product (e. g. HiPP Sondennahrung), but the amount of calories will not be changed.

In clinical routine, energy needs are usually estimated using the Harris-Benedict-formula, based on body weight, height, sex and age. However, this formula only provides approximate values. Therefore, in this study, indirect calorimetry is used to obtain precise values of energy needs. The German version of the International Physical Activity Questionnaire Short Last 7 Days Self-administered Format (IPAQ) is used for determining the physical activity level. The total energy requirement is calculated by adding the resting energy expenditure and the activity-related calorie requirement.

In the control group, 100% of the estimated calorie requirement is administered with the goal of covering energy needs and stabilizing body weight. The hypercaloric diet in the intervention group consists in 120% of the calorie requirement determined by indirect calorimetry. Resting energy expenditure in ALS patients is 14% higher than in a healthy control cohort. We assume that activity-related energy expenditure is increased similarly. Therefore, the hypercaloric diet consisting in 120% of calorie requirement aims to cover these additional energy needs. Similarly, a recent study in patients with PEG used 125% of calorie requirement.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Possible, probable (clinically or laboratory) or definite ALS according to the revised version of the El Escorial World Federation of Neurology criteria 1
  • Loss of ALS functional rating scale revised (ALSFRS-R) of ≥ 0.33 points per month since onset (first paresis) based on the formula: (48 - Score at Screening Visit) / (Months between Onset and Screening Visit)
  • Nutrition via PEG
  • Age ≥18 years
  • Intake of a stable dose of riluzole for at least 4 weeks, or no riluzole
  • Capable of thoroughly understanding all information given and giving full informed consent according to GCP

Exclusion criteria

  • Previous participation in another interventional study within the preceding 4 weeks
  • Absence of adequate social support and cooperation, or personal motivation (in the judgment of the investigator) to complete the study satisfactorily
  • Pregnancy or breast-feeding females
  • Evidence of a major psychiatric disorder or clinically evident dementia

Treatment and study plan

100% of individual calory requirement

Dietary Supplement

Patients receive any PEG nutrition containing the calory requirement as determined by indirect calorimetry, physical activity score and the randomized group.

120% of individual calory requirement

Dietary Supplement

Patients receive any PEG nutrition containing the calory requirement as determined by indirect calorimetry, physical activity score and the randomized group.

Primary outcomes

  1. Neurofilament light chain (NfL) in serum

    Time frame: 6 months

    Change of neurofilament light chain (NfL) concentration in serum after 6 months compared to baseline. The change will be measured as individual NfL slope from baseline to 6 months (change per month).

Secondary outcomes

  1. Survival

    Time frame: 6 months

    time to death or tracheostomy

  2. ALS functional rating scale revised (ALSFRS-R)

    Time frame: 6 months

    Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R) score, measured as individual slope (loss of points per month)

  3. Body mass index (BMI)

    Time frame: 6 months

    Body Mass Index (BMI), weight (in kg) and height (in m) will be combined to report BMI in kg/m^2

  4. Slow vital capacity

    Time frame: 6 months

    Slow vital capacity (sVC)

  5. Resting energy expenditure (REE)

    Time frame: 6 months

    Resting Energy Expenditure (REE), measured by indirect calorimetry

  6. Individual Quality of Life

    Time frame: 6 months

    Individual Quality of Life, measured by the Euro Quality of Life (EQ-5D-5L) questionnaire

  7. Appetite

    Time frame: 6 months

    Appetite, measured by the Council of Appetite Questionnaire (CNAQ)

  8. Eating habits

    Time frame: 6 months

    Eating Habits, evaluated by the Ulm Nutrition Questionnaire (UNQ; see LIPCAL study)

  9. Adverse Events

    Time frame: 6 months

    Terms and frequencies of adverse eves (AEs) and serious adverse events (SAEs)

  10. Fatt mass

    Time frame: 6 months

    Fat mass (% of total body mass), measured by bioelectrical impedance analysis (BIA)

  11. Total Body Water

    Time frame: 6 months

    total body water (% of total body mass), measured by bioelectrical impedance analysis (BIA)

  12. Muscle Mass

    Time frame: 6 months

    muscle mass (% of total body mass) measured by bioelectrical impedance analysis (BIA)

  13. Fat Free Mass

    Time frame: 6 months

    fat free mass (% of total body mass), measured by bioelectrical impedance analysis (BIA)

  14. Body Cell Mass

    Time frame: 6 months

    body cell mass (% of total body mass), measured by bioelectrical impedance analysis (BIA)

  15. Extracellular Mass

    Time frame: 6 months

    extracellular mass (% of total body mass), measured by bioelectrical impedance analysis (BIA)

  16. Lean Body Mass

    Time frame: 6 months

    lean body mass (% of total body mass), measured by bioelectrical impedance analysis (BIA)

  17. Beta Hydroxybutyrate

    Time frame: 6 months

    Beta Hydroxybutyrate serum levels

  18. Acetoacetate

    Time frame: 6 months

    Acetoacetate serum levels

  19. Acetone

    Time frame: 6 months

    Acetone concentration in urine

  20. Lipid metabolism

    Time frame: 6 months

    Cholesterol serum levels

  21. Lipid metabolism

    Time frame: 6 months

    High-density-lipoprotein (HDL) serum levels

  22. Lipid metabolism

    Time frame: 6 months

    Low-density-lipoprotein (HDL) serum levels

Study contacts

Contact information is provided by the study sponsor or research team.

Christine Herrmann, Dr.

CONTACT

[email protected]

0049 731 177 5374

Johannes Dorst, Prof. Dr.

CONTACT

[email protected]

0049 731 177 5285

Sponsors and collaborators

Lead sponsor

University of Ulm

Other

Registry information

Acronym: PEGASUS

Important dates

Study start
2025
Primary completion
2031
Study completion
2031
First posted
Mar 14, 2025
Registry last updated
May 6, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.